Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cosciens Biopharma Inc (CSCI.TO)

Cosciens Biopharma Inc (CSCI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 9,103
  • Shares Outstanding, K 3,183
  • Annual Sales, $ 9,587 K
  • Annual Income, $ -15,309 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.70
  • Price/Sales 0.72
  • Price/Cash Flow N/A
  • Price/Book 1.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +2.14%
on 12/16/25
3.29 -13.07%
on 11/27/25
-0.12 (-4.03%)
since 11/19/25
3-Month
2.80 +2.14%
on 12/16/25
3.84 -25.52%
on 09/23/25
-0.76 (-20.99%)
since 09/19/25
52-Week
2.80 +2.14%
on 12/16/25
6.46 -55.73%
on 03/19/25
-1.07 (-27.23%)
since 12/19/24

Most Recent Stories

More News
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“ COSCIENS ” or the “ Company ”), a life sciences company focused on pharmaceutical therapies,...

CSCI.TO : 2.86 (-5.30%)
CSCIF : 2.1700 (+2.12%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Announces Leadership Change

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and...

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma: Q3 Earnings Snapshot

COSCIENS Biopharma: Q3 Earnings Snapshot

CSCI.TO : 2.86 (-5.30%)
COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS voluntarily delists from Nasdaq, while retaining the Company’s listing on the TSX COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs....

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma: Q2 Earnings Snapshot

COSCIENS Biopharma: Q2 Earnings Snapshot

CSCI.TO : 2.86 (-5.30%)
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq , while retaining the Company’s listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS...

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.

/CNW/ - Goodwood Fund and Puccetti Funds Management Inc. (collectively, "Goodwood") announced today that Goodwood has notified COSCIENS Biopharma Inc. (NASDAQ:...

CSCI.TO : 2.86 (-5.30%)
CSCI : 2.72 (-11.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction...

See More

Key Turning Points

3rd Resistance Point 3.15
2nd Resistance Point 3.09
1st Resistance Point 2.97
Last Price 2.86
1st Support Level 2.79
2nd Support Level 2.73
3rd Support Level 2.61

See More

52-Week High 6.46
Fibonacci 61.8% 5.06
Fibonacci 50% 4.63
Fibonacci 38.2% 4.20
Last Price 2.86
52-Week Low 2.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar